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tionnaire (ITSQ) for use in 18 countries in 22 languages, includ-
ing Czech, Greek, Hungarian, Romanian, Russian, Serbian,
Slovenian and Turkish. The questionnaire was developed in 2003
and was designed to assess the satisfaction with insulin treatment
by patients with diabetes. METHODS: The methodology
employed was: 2 forward translations and their reconciliation, 2
back translations, back translation review, client afﬁliate review,
linguistic validation interviews with 5 patients with diabetes and
2 proof readings. RESULTS: While the majority of wording was
easily agreed upon, certain words and phrases were more
troublesome. Issues and solutions included: “How much bother”
was difﬁcult to render in some languages. In Bulgarian, for
example, this was translated as “How difﬁcult”, with the context
implying “being annoying and causing frustration”. In Roma-
nian, “burdensome” was rendered as “troublesome”, and
“fatigue” was rendered as “extreme tiredness”, as there is no
direct translation of these English terms. Russian patients could
not understand the direct translation of “avoid” (as in “avoid
symptoms of hyperglycaemia”)—this was revised to read “will
not have”. Slovenian patients could not understand the transla-
tion of “stability” (as in “stability of blood sugar levels”)—this
was revised to a word meaning “permanency” or “invariability”.
CONCLUSION: The ITSQ has been translated and linguistically
validated and is now available for use in 18 countries (including
8 Eastern European nations) and in 22 languages. This project
has also highlighted the importance of linguistic validation
interviews.
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OBJECTIVES: To assess whether treatment satisfaction is asso-
ciated with effectiveness of OHA and with the experience of
hypoglycemic symptoms among patients with T2DM who added
sulfonylureas (SU) or glitazone (PPAR) to metformin (MF).
METHODS: A retrospective clinical chart review and patient
survey (June 2006–February 2007) was conducted in 7 countries
(Finland, France, Germany, Norway, Poland, Spain, UK).
Patients recruited (aged 30 years at T2DM diagnosis) added SU
or PPARf¥-agonist to previous MF. Patients with gestational
diabetes and those using insulin were excluded. The Treatment
Satisfaction Questionnaire for Medication (TSQM), a 14-item
grouped in 4 domains validated instrument, was used to measure
patients’ treatment satisfaction with current OHA. Adequate
glycemic control was deﬁned according to the IDF-2005 recom-
mendations as A1C < 6.5%. Unadjusted differences in treatment
satisfaction by experience of hypoglycemia and glycemic control
was assessed using the chi-square test. RESULTS: 1709 patients
were included. Average age was 63 (SD = 11) years and 45%
were female. The mean A1C level was 7.1% (SD = 1.1), while
28% (477 patients) had adequate glycemic control. 652 (38%)
reported hypoglycemic symptoms of varying severity and fre-
quency. Relative to those reporting experience of hypoglycemic
symptoms, patients not experiencing hypoglycemic symptoms
report higher scores on all domains of TSQM: effectiveness (71.5
vs. 67.8), side effect (91.9 vs. 81.4), convenience (77.0 vs. 73.4),
and global satisfaction (76.3 vs. 71.6) (all p < 0.0001). Treat-
ment satisfaction with therapy was higher for patients with
adequate glycemic control than for those without, for all TSQM
domains: effectiveness (71.3 vs. 69.6; p = 0.08), side effect (89.5
vs. 87.1; p = 0.0339), and convenience (76.9 vs. 75.0; p = 0.14)
and global satisfaction ((75.8 vs. 74.0; p = 0.0436). CONCLU-
SION: Twenty-eight percent of patients had A1C < 6.5% while
38% experienced hypoglycemic symptoms. Patient-reported
experience of hypoglycemia is associated with statistically signiﬁ-
cant lower treatment satisfaction. Global satisfaction with treat-
ment is statistically signiﬁcantly higher among patients with
adequate treatment control.
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OBJECTIVES: Patients with Type 2 Diabetes (T2D) not well
controlled with oral antidiabetic drugs (OAD) often postpone the
start of insulin therapy (IT). The reasons of this so called “psy-
chological insulin resistance” are multifaceted. We have devel-
oped and validated a simple tool to identify “barriers to insulin”
the “BIT” questionnaire. METHODS: Scale development was
based on principle component analysis in two cross-sectional
studies in insulin naïve patients with T2D (ﬁrst sample n = 448;
cross-validated in an independent sample of 449 patients).
RESULTS: Analysis in the ﬁrst sample yielded 5 components that
accounts 74.7% of the variance based on 14 items and 69.4% in
the second sample. Conﬁrmatory factor analysis indicated a good
model ﬁt with RMSEA = 0.04 and CFI = 0.97. The 5 compo-
nents are: Expectation regarding insulin-related outcome; fear of
injection and blood glucose self testing; expected hardship from
IT; stigmatization by IT; fear of hypoglycaemia. In daily practice
conditions the questionnaire can be used to identify BIT in
general by focusing on the “sum score. In addition physicians
and diabetes educators can go more in detail when analysing the
results of the 5 components, separately. So objections against IT
can be discussed in total or physicians/educators can focus on
“speciﬁc barriers”. The “BIT” can also be used to investigate
scientiﬁc questions regarding “psychological insulin resistance”.
Scientiﬁc view: We investigated patients with T2D on IT. The
result of the BIT differs extremely between patients having good/
worse glycemic control. CONCLUSION: The “BIT” is the ﬁrst
valid and reliable instrument to measure “psychological insulin
resistance” in patients with T2D. Patients with T2D need 2–3
minutes to ﬁll the BIT. The results should be discussed with the
patients. Established barriers could be broken down systemati-
cally. This could reduce the individual workload. In addition the
BIT is a valid tool to use in research.
PDB78
COMPARISONS BETWEEN ITEQ AND DTSQ IN A SAMPLE OF
TYPE 2 DIABETES MELLITUS PATIENTS
Moock J, Kubiak T, Dingler D, Kohlmann T
University of Greifswald, Greifswald, Germany
OBJECTIVES: Treatment satisfaction (TS) is a key outcome
criterion of diabetes therapy. Existing instruments mainly address
general aspects of TS. In contrast the new Insulin Treatment
Experience Questionnaire (ITEQ) was developed in German lan-
guage to assess subtle but relevant effects of TS in a wide range
of insulin therapy regimens (e.g. BOT, intensiﬁed insulin therapy
with or without insulin analogues) focusing on T2DM patients.
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